Matinas BioPharma to Merge with GH Power, Sell Drug Asset to Azurity
Matinas BioPharma is pivoting from biopharma to clean energy via a merger with GH Power while offloading its lead drug platform to Azurity Pharmaceuticals.
Matinas BioPharma announced a dual-pronged strategic overhaul Wednesday, revealing a business combination with GH Power that will create a publicly traded clean energy company while simultaneously signing a definitive agreement to sell its lipid nanocrystal platform technology and lead drug candidate MAT2203 to Azurity Pharmaceuticals.
The merger with GH Power is designed to produce a publicly listed enterprise focused on modular carbon-free energy, green hydrogen production, critical materials sourcing, and broader industrial decarbonization — sectors that have attracted significant investor interest amid global efforts to reduce greenhouse gas emissions.
Read more Apple and Google Set to Deepen AI Partnership After OpenAI Suit →
By divesting its LNC platform and MAT2203 to Azurity, Matinas is effectively exiting the pharmaceutical development space entirely, clearing the balance sheet of drug-development liabilities and redeploying whatever proceeds emerge toward the capital-intensive clean energy buildout the GH Power combination demands.
The strategic pivot marks a sharp departure for Matinas, which had spent years advancing MAT2203 — an oral antifungal therapy built on its proprietary lipid nanocrystal delivery technology — through clinical development. Azurity, a specialty pharma firm, gains a differentiated drug-delivery platform alongside a clinical-stage asset in one transaction.
The combined clean energy entity's focus on modular, carbon-free power generation and green hydrogen positions it within one of the fastest-growing verticals in the energy transition, though execution risk remains high given the early-stage nature of many green hydrogen ventures. Continue reading at GlobalNewswire.
